Clinical Trials Directory

Trials / Conditions / B-cell Lymphoma Recurrent

B-cell Lymphoma Recurrent

17 registered clinical trials studyying B-cell Lymphoma Recurrent — 5 currently recruiting.

StatusTrialSponsorPhase
TerminatedAxicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphom
NCT06912529
Universität MünsterPhase 2
RecruitingCD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
NCT06445803
Rong TaoPhase 1
RecruitingSelinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma
NCT06552559
Samsung Medical CenterPhase 1 / Phase 2
RecruitingTreatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produc
NCT06378190
Instituto de Investigación Biomédica de SalamancaPhase 1 / Phase 2
Not Yet RecruitingSafety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lympho
NCT05909098
Xiangyang No.1 People's HospitalPhase 1 / Phase 2
RecruitingClinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lympho
NCT05705570
Nelson HamerschlakPhase 1
TerminatedTargeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma
NCT05318963
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1
Active Not RecruitingAxi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autolog
NCT04531046
The Lymphoma Academic Research OrganisationPhase 2
UnknownInduced-T Cell Like NK Cells for B Cell Malignancies
NCT04747093
Nanfang Hospital, Southern Medical UniversityPhase 1 / Phase 2
CompletedCAR T Cell Therapy Related Cardiovascular Outcomes
NCT05130489
University College London Hospitals—
UnknownA Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
NCT04304040
Beijing InnoCare Pharma Tech Co., Ltd.Phase 1 / Phase 2
UnknownCD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL
NCT04303247
Xinqiao Hospital of ChongqingEARLY_Phase 1
Active Not RecruitingCD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies
NCT04214886
Loyola UniversityPhase 1
Active Not RecruitingMB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
NCT03853616
Miltenyi Biomedicine GmbHPhase 1
CompletedMB-CART20.1 Lymphoma
NCT03664635
Miltenyi Biomedicine GmbHPhase 1 / Phase 2
UnknownA Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies
NCT03757000
Shanghai YingLi Pharmaceutical Co. Ltd.Phase 1
CompletedCombination of Rituximab and NK Immunotherapy for B Lymphoma
NCT02843061
Fuda Cancer Hospital, GuangzhouPhase 1 / Phase 2